15148-73-9

Basic information

• Product Name: 4-(bromomethyl)-N,N-diethylbenzenesulfonamide
• Synonyms: 4-(bromomethyl)-N,N-diethylbenzenesulfonamide
• CAS NO: 15148-73-9
• Molecular Weight: 306.224
• Mol File: 15148-73-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(bromomethyl)-N,N-diethylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(bromomethyl)-N,N-diethylbenzenesulfonamide(15148-73-9)
• EPA Substance Registry System: 4-(bromomethyl)-N,N-diethylbenzenesulfonamide(15148-73-9)

Safety Data

• Hazardous Substances Data: 15148-73-9(Hazardous Substances Data)

Upstream product

• 66176-39-4 4-(bromomethyl)benzene-1-sulfonyl chloride 
• 109-89-7 diethylamine 

Downstream Products

• 855307-66-3 4-(3-amino-indazol-1-ylmethyl)-N,N-diethyl-benzenesulfonamide 
• 212262-24-3 4-(2-thiophen-3-yl-ethoxymethyl)-benzenesulfonyl chloride 
• 212262-19-6 N,N-diethyl-4-(2-thiophen-3-yl-ethoxymethyl)-benzenesulfonamide 

Relevant articles and documents

Synthesis and initial biological evaluation of new mimics of the LXR-modulator 22(S)-hydroxycholesterol

The generic, synthetic oxysterol 22(S)-hydroxycholesterol (22SHC) has shown antagonistic effects towards liver X receptor (LXR) in vitro and promising effects on plasma triacylglycerol level and body weight-gain in animal studies.1,2 On the contrary, the endogenic LXR agonist 22(R)-hydroxycholesterol (22RHC) and synthetic LXR agonists convincingly have shown agonistic effects on genes involved in lipogenesis, and inhibitory effects on cell proliferation in vitro and in vivo.3 We hypothesized that the carbon side chain containing the hydroxyl group at the 22-position was a pharmacophore affecting these opposite effects on LXR. This prompted us to initiate a rational drug design incorporating the 22-hydroxylated 20-27 cholesterol moiety into cholesterol-mimicking building blocks. The two enantiomers of the 22-hydroxylated 20-27 cholesterol moiety were synthesized with an excellent enantiomeric excess and the stereochemistry are supported by X-ray crystallography. Molecular modelling of the new compounds showed promising LXR selectivity (LXRβ over LXRα) and initial in vitro biological evaluation in human myotubes showed that compound 16b had agonistic effects on the gene expression of SCD1 and increased lipogenesis.

4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY

The present invention relates to 4-phenyl-5-oxo-l,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (l-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (l-4C)allcyl, (2-4C)alkenyl, (2-4C)- alkynyl, (1 -4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)- heteroaryl, both substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (l-4C)alkyl, (l-4C)alkoxy , (l-4C)alkylthio and (di)(l-4C)- alkylamino. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 4-phenyl-5-oxo-l, 4,5,6, 7,8-hexahydro- quinoline derivatives in therapy, more specifically for the treatment of infertility

Chemical synthesis at solid interfaces. On the use of conducting polythiophenes equipped of adequate linkers allowing a facile and highly selective cathodic S-N bond scission with a fully regenerating resin process

Electrogenerated polythiophenes were evaluated as Merrifield-like resins for the anchoring of amine functions together with deprotection processes. Suitable linkers were terminated with a fully regenerable aromatic sulfonamide moiety. The S-N bond was cleaved to liberate the amine with high selectivity under very mild conditions by cathodic means with amine liberation. Moreover a facile recycling process of the resin allows the further grafting of various amine functions.